首页> 外文期刊>Molecular simulation >New 1(2H)-phthalazinone derivatives as potent nonpeptidic HIV-1 protease inhibitors: molecular docking studies, molecular dynamics simulation, oral bioavailability and ADME prediction
【24h】

New 1(2H)-phthalazinone derivatives as potent nonpeptidic HIV-1 protease inhibitors: molecular docking studies, molecular dynamics simulation, oral bioavailability and ADME prediction

机译:新的1(2H)-酞嗪酮衍生物可作为有效的非肽类HIV-1蛋白酶抑制剂:分子对接研究,分子动力学模拟,口服生物利用度和ADME预测

获取原文
获取原文并翻译 | 示例
           

摘要

Molecular docking simulations of compounds 1-7, the newly synthesised 1(2H)-phthalazinone derivatives with N-(dimethylamino)ethyl pendant arm, as potent inhibitors of HIV-1 protease (HIV-1 PR) were performed. The results of calculations show that compounds 1-7 can form stable complexes with HIV-1 PR and their inhibitory action is mainly based on combination of intermolecular hydrogen bonds and ionic interactions between flexible cationic ammonium moiety of ligands and deprotonated carboxylic residues Asp25 and Asp29 of the target receptor. Molecular dynamics calculation in explicit water environment of the best ranked complex of compound 3 with HIV-1 PR reveals its high stability with conservation of strong salt bridge interactions during all simulation time. Per-residue decomposition of the binding free energy of HIV-1 PR complex with compound 3 calculated with the MM-PBSA method shows electrostatic and van der Waals interactions as the main favourable components. Estimated oral bioavailability and calculated absorption, distribution, metabolism and excretion (ADME) descriptors, namely, intestinal absorption, aqueous solubility and blood-brain barrier penetration, for compounds 1-7 indicate their good pharmacokinetic profile in humans after oral administration. Enthalpically favourable contribution of ligand-receptor salt bridge interactions and hydrogen bonds to binding free energy in calculated complexes of compounds 1-7 with HIV-1 PR also suggests a potent feature to combat a drug resistance to HIV-1 PR inhibitors.
机译:进行了化合物1-7的分子对接模拟,该化合物是新合成的具有N-(二甲基氨基)乙基侧链的1(2H)-酞嗪酮衍生物,作为HIV-1蛋白酶(HIV-1 PR)的有效抑制剂。计算结果表明,化合物1-7可以与HIV-1 PR形成稳定的复合物,其抑制作用主要是基于分子间氢键以及配体的柔性阳离子铵部分与去质子化羧酸残基Asp25和Asp29之间的离子相互作用的结合。目标受体。化合物3与HIV-1 PR的最佳配合物在显性水环境中的分子动力学计算表明,该化合物具有很高的稳定性,并在所有模拟时间内均保留了强的盐桥相互作用。使用MM-PBSA方法计算的HIV-1 PR复合物与化合物3的结合自由能的残基分解表明,静电和范德华相互作用是主要的有利成分。对于化合物1-7,估计的口服生物利用度和计算的吸收,分布,代谢和排泄(ADME)描述词,即肠道吸收,水溶性和血脑屏障渗透性,表明它们在口服后对人的药代动力学良好。在化合物1-7与HIV-1 PR的复合物中计算得出的配体-受体盐桥相互作用和氢键对结合自由能的极大有利贡献还表明,它具有对抗HIV-1 PR抑制剂的抗药性的强大功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号